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Abstract
This paper summarizes the methodology for the registry of suspected COVID-19 in
emergency care (RECOVER), a large clinical registry of patients from155UnitedStates
(US) emergency departments (EDs) in 27 states tested for SARS-CoV-2 from March–
September2020. The initial goals are toderive and test: (1) a pretest probability instru-
ment for prediction of SARS-CoV-2 test results, and from this instrument, a set of sim-
ple criteria to exclude COVID-19 (the COVID-19 Rule-Out Criteria—the CORC rule),
and (2) a prognostic instrument for those with COVID-19. Patient eligibility included
any EDpatient tested for SARS-CoV-2with a nasal or oropharyngeal swab. Abstracted
clinical data included 204 variables representing the earliest manifestation of infec-
tion, including week of testing, demographics, symptoms, exposure risk, past medical
history, test results, admission status, and outcomes 30 days later. In addition to the
primary goals, the registry will provide a vital platform for characterizing the course,
epidemiology, clinical features, and prognosis of patients tested for COVID-19 in the
ED setting.
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1 BACKGROUND
The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-
2 has impacted citizens internationally. As of October 12, 2020, there
have been over 7 million infections and 215,000 deaths across the
United States (US), with the number of cases growing.1 Much remains
unknown regarding the actual number of cases and evolving epidemi-
ology of COVID-19 in the United States.2–5 Factors limiting current
knowledge include the current lack of systematically collected data
from patients with atypical symptoms and problems associated with
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diagnostic test availability and accuracy.2,4,6,7 In addition, the clinical
picture of SARS-CoV-2 infection has a wide range of presenting symp-
toms, followed by a wide spectrum of associated complications and
outcomes.8–12
Theemergencydepartment (ED) is a key location for disease surveil-
lance and collection of data to answer critically important questions
about COVID-19 prediction, prognosis, and outcome. Furthermore,
the ED is the catchment location for the population who may not have
access to routine medical care and may use the ED exclusively for on-
demand care and may be most threatened by this outbreak. Toward
that goal, this report describes the methodology for the creation and
execution of the registry of suspected COVID-19 in emergency care
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(RECOVER), a national registry of ED patients tested for severe acute
respiratory syndrome, coronavirus-2 (SARS-CoV-2). The primary goals
of this work involve the prediction of positive testing for SARS-CoV-
2 and prognosis of patients with infection. RECOVER will also provide
the platform for answeringmyriad other COVID-19 questions.
2 METHODS
2.1 History and rationale for the registry
The RECOVER registry is the result of a grass-roots effort of a con-
sortium of 45 emergency medicine clinician investigators from 27
US states representing both community and academic centers. The
registry had 2 preliminary aims. First, creation of a quantitative pretest
probability scoring system to predict a positive SARS-CoV-2 test, and
relatedly the derivation and internal validation of a prediction rule to
identify those at very low probability of disease (COVID-19 Rule Out
Criteria-CORC rule). The second aim is the derivation and internal
validation of a set of criteria to predict the development of severe
COVID-19. Rationale for the RECOVER registry hinges on the fact that
the ED represents a pivotal site for syndromic surveillance because
of the high volume of undifferentiated patients and the spectrum of
illness that can be captured early in the disease course. In 2016, US
EDs had >145 million encounters each year, and we anticipated that
millions of ED patients would be evaluated for suspected COVID-19
in 2020.13 Additionally, because the ED interfaces with both outpa-
tient and inpatient medical care, the critical question of SARS-CoV-2
infection status affects decisions to admit or discharge the patient,
return to work, need for home isolation, and the location of hospital
admission.
Recognizing inMarch of 2020 that a vaccine was at least 12months
away, and SARS-CoV-2 would likely remain endemic in the years to
come, the first aim focused on developing simple clinical criteria to
exclude COVID-19 at the bedside, without the need for blood or radio-
graphic testing. In many EDs, the turnaround time for laboratory test-
ing for SARS-CoV-2 nucleic acid takes longer than 24 hours and rapid
point-of-care assays have been hampered by low sensitivity, with one
systematic review finding the sensitivity in pooled data at only 56% for
antigen tests.7 Reports of low test sensitivity for swab reverse tran-
scriptase polymerase chain reaction (rtPCR) tests, and tests that use
other nucleic amplification techniques, have raised concern.4,6,14 With-
out specific reliable exclusionary criteria, emergency care clinicians
cannotmakeexpeditious decisions for eachof the tens ofmillions of ED
patients with symptoms consistent with COVID-19, nor can the emer-
gency care system operate efficiently with the potential need to order
a SARS-CoV-2 test for each of these patients.
2.2 Design and setting
The registry is being completed by a network of 45 site investigators
from 27 states listed in Figure 1. Most of the sites are part of hospital
systems, and as a result, data are derived from patients seen at 155
hospitals. The majority of hospitals are located in metropolitan areas,
and≈60% are community hospitals without residency programs.
2.3 Registry development
The RECOVER registry was built using RedCAP and includes 204
explicitly defined questions resulting in 360 discrete possible answers
among seven domains: (1) Visit Information (18 questions), (2) Demo-
graphics, Symptoms and Risk Factors (11 questions), (3) Vital Signs (16
questions), (4) PastMedicalHistory (39questions), (5)CurrentMedica-
tions (18 questions), (6) Test Results (47 questions), and (7) Outcomes
(48 questions). Trained abstractors obtained data from the local elec-
tronic medical record. Using a combination of computer scripts and
the real-time work of trained research associates, the RECOVER reg-
istry transforms information stored in the electronic medical record
into a REDCap (http://www.projectredcap.org) database suitable for
further transformation into research manuscripts. Using the first ED
visit that occurred in the 14 days before testing (the maximum prob-
able incubation period), allows the data set to collect atypical and early
symptoms.
To accelerate the time frame to completion, the data collection
formwas designed and tested to allow completion by research person-
nel with basic medical knowledge, with minimal supervision. We used
branching logic where possible to improve efficiency (eg, only show a
list of possible statins if previous answer to statin use is “yes”). The
form includes features to avoid protected health informationwhile still
record the timing of enrollment, tests, and outcomes. For example, the
form collects the week, month, and year of the index ED visit, as well
as the first 4 digits of the patients’ ZIP code. These are not protected
health information but allow a close estimate to when the patient was
enrolled and their region of residence, which is important for epidemi-
ological surveillance.
This form was pilot-tested at 19 sites before network-wide imple-
mentation. This pilot testing resulted in multiple changes to clarify
fields, alter input ranges, and methods of questioning, and response
options. As one example, this process resulted in adding more detail
on timing of all tests relative to the index visit and results of antibody
testing for SARS-CoV-2. Additionally, in April 2020 at Indiana Uni-
versity, using a convenience sample of 50 charts, 2 abstractors, each
of whom had experience using REDcap and with 1 hour of training
from the site principal investigator, double coded 2 REDcap forms
for each of the 50 patients and compared results for the questions
in Table 1, which indicated 98% homology in answers (2% variation
occurring in the community risk question). The entire contents of




Each site investigator was given an extensive written manual of
operations describing patient eligibility and the goals of the registry
with specific instructions on each form and field. The registry uses
REDcap features to force data entry for critical fields, perform error
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F IGURE 1 Diagram of administrative and scientific oversight of the RECOVER registry and network
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TABLE 1 Symptoms and risk factors for severe acute respiratory
novel coronavirus 2 infection recorded in the registry*
Symptoms Risk factors
Ear pain None
Rhinorrhea Travel to the United States from a
country with known endemic disease




Unemployed or retired, social contact




Employed, non-health care worker,




Employed, health care worker with
patient contact
Chest pain Caretaker, partner, or family member in
close contact with a personwith
known or suspected COVID-19




Respiratory distress/failure Institutional exposure: nursing home
History of fever Institutional exposure: assisted living
facility
Fatigue/malaise Institutional exposure: prison/jail or
other correctional facility
Muscle aches (myalgia) Group home

















*Examples of answer options to 2 of 204 questions in the registry.
checking, forcing functions ensure correct alpha-numeric content, and
ranges for numeric data. By rule, if the answer to a question was not
documented, the field is codedasnegative—the sameas if the chart had
deliberate statement about the absence of the datum.
The RECOVER registry, and its interaction with 45 contributing
sites, are overseen by 2 cores: the administrative core (3 individuals,
including a program manager, service and data use agreement coordi-
nator, and grants manager), and a Steering Committee (authors JAK,
CK, CAC, DMC, KEN) that provides overall study guidance, including
data use issues. The names of the sites and the governance overview
are shown in Figure 1. The 45 site principal investigators are supported
by a full-time programmanager (KLP) at the Indiana University School
of Medicine who, with input from the overall principal investigator,
answers questions about data entry and ensures each site has support-
ing documents including the detailed guidance and FAQ document.
The protocol for the registry was reviewed by the Institutional
Review Boards at all participating sites, and with the exception
of one site, the Institutional Review Boards deemed the protocol
exempted from human subjects research. One Institutional Review
Board deemed the 4-digit zip code to represent protected health infor-
mation and approved the protocol under waiver of authorization for
participation in research as well as informed consent; therefore the zip
codewas reduced to 3 digits.
2.4 Patient selection
Figure2provides anoverviewof patient identification and flowof data.
Patients selected for the registry included ED patients who had any
diagnostic test for SARS-CoV-2, located by electronic query for charge
procedure code 87635, which is unique for SARS-CoV-2 testing. All
SARs-CoV-2 tests were based on molecular testing for SARS-CoV-2
RNA as opposed to antigen testing. Because many patients may have
had a prior ED visit without testing, the “index visit” was defined as any
EDvisit that occurredwithin 14days before the swab testing for SARS-
CoV-2 (Figure 3), that did not meet specific exclusions. Exclusions to
a prior ED visit within the previous 14 days being coded as the “index
visit” included predefined circumstances where that ED visit lacked a
reasonable probability of being related to possible COVID-19 symp-
toms: (1) trauma, (2) alcohol or drug intoxication, (3) poisoning, (4) sui-
cidality, (5) suspected rape or other domestic violence, (6) involuntary
commitment, (7) other isolated chief complaints clearly not related to
COVID-19 (eg, suture removal), and (8) testing done purely for policy
(eg, any admitted patient), rather than testing based on clinical suspi-
cion. Patients were enrolled fromMarch–September 2020 with intent
to enroll eligible patients consecutively.
2.5 Outcomes—COVID-19+ and severe
COVID-19
The primary outcomes were COVID-19 diagnosis and severe COVID-
19. The criterion standard for COVID-19+ was a positive swab for
SARS-CoV-2 nucleic acid by a molecular detection (rtPCR or other
amplification technique) or positive convalescent sera for anti-SARS-
CoV-2 IgM or IgG.15,16 We recognize the imperfect test sensitivity
of the swab-based rtPCR and also serum antibody testing.17 The
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F IGURE 2 Diagram of data flow for the RECOVER registry
F IGURE 3 Timeline of eligibility and follow-up. The index visit
refers to the first ED visit that occurred within the previous 14 days of
SARS-CoV-2 testing. In many cases, the index visit is the same as the
day of testing (day 0). All patients are followed for outcomes up to 30
days after the day of SARS-CoV-2 testing
most pragmatic method to categorize patients as “clinically negative”
for COVID-19 disease is the absence of return visit for 30 days, or
consistently negative testing. Sites were encouraged in the course of
investigating the index visit and 30-day outcomes to review any and all
available data from clinical care data networks that allowed access to
medical records from other hospitals. For example, in Indianapolis, the
investigators examined the CareWeb medical record of the Indiana
Health Information Exchange (https://www.ihie.org/) which includes
results from over 100 EDs in Indiana. In the case of serial testing, any
positive test within 30 days would be considered COVID-19+, unless
the record clearly indicates a negative test at the index visit, followed
by>7 days of no symptoms, then new symptoms, or exposure and then
a new positive test. These patients were excluded from CORC rule
derivationbecause theirCOVID-19status at the indexvisitwas consid-
eredambiguous. Thedefinitionof “severeCOVID-19”wasdeath, or the
decision to perform endotracheal intubation followed by mechanical
ventilation for>24hourswithin 30 days of a positive SARS-CoV-2 test.
2.6 Role of funding
Funding was derived from unrestricted internal monies from the
Department of Emergency Medicine at Indiana University School of
Medicine under the direction of the senior principal investigator (JAK).
2.7 Data analysis and sample size
The first defined aim of the study was to develop pragmatic criteria for
a COVID-19 Rule Out Criteria-CORC rule that predicts an acceptably
low probability of SARS-CoV-2 infection to forego testing. The general
analytic strategy will encompass the use of logistic regression with
positive SARS-CoV-2 testing as the primary outcome, and demo-
graphic, symptomatic, risk factors, vital signs, and past medical history
as the predictor variables. The logistic regression coefficients will
be used to create a pretest probability scoring system. To make the
CORC rule widely applicable, the predictor variables will only include
variables available in almost all cases at the bedside, including demo-
graphics, patient-reported exposure, vital signs, history of present
illness, medications, past medical history, and findings from physical
examination. The sample size estimate for the first aim was based on
preliminary work done in March 2020, including a survey of 20 par-
ticipating sites. We anticipated a SARS-CoV-2 positive rate between
8% to 66%, with an average of 31% (ie, 69% of testing negative). We
also anticipated that ∼15% of the COVID-19 patients would have
atypical presentations and ≈20% would go on to require mechanical
ventilation or experience death, defining severe disease. Thus, a
minimum sample size of 20,000 patients was anticipated to produce
≈6000 positive cases, including 600 with atypical features and 800
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with severe disease. These samples would allow sufficient patients
to derive pretest probability on a random sample of 10,000 patients
using bivariate-multivariable approach and assuming a traditional 10:1
rule for the ratio of outcomes to predictors in a logistic regression
equation; thus, this sample will allow inclusion of at least 25 predictor
variables without significant overfit for atypical presentations.18
The derived rule will be tested in the remaining independent
sample.
2.8 Ancillary studies and data sharing
Each site is asked to enroll at least 500 patients with a complete RED-
Cap form before request for data access. Requests for data access
require submission of aREDCap survey that asks 5questions: (1) inves-
tigator name and contact, (2) title of work, (3) brief description, (4)
study objective(s), and (5) method of analysis. As of October 12, 2020,
site investigators, or their local collaborators, have submitted 39 pro-
posals for ancillary studies. TheSteeringCommittee reviews these sub-
missions on an ad-hoc basis. Data will be embargoed from the gen-
eral public until approximately June 1, 2021 and thereafter will be
freely, publicly availablewith awritten request (including contact infor-
mation, title and main objective of the work, and brief analytic plan),
approved by the Steering Committee. The RECOVER data are devoid
of protected health information.
2.9 Progress and timeline
The goal was to complete 20,000 forms within 6 months of study initi-
ation (ie, September 2020). As of October 12, 2020, over 31,500 forms
have been uploaded. The end of data collection is planned for October
16, 2020.
3 LIMITATIONS
This registry is restricted to ED patients who received a SARS-CoV-
2 diagnostic test. This leads to bias toward reporting characteristics
of patients with overt symptoms, and the risk of missing patients with
atypical or no symptoms. Furthermore, there was variation in national
SARS-CoV-2 testing strategy over time driven in part by availability
of the different tests and the frequently changing recommendations
in testing strategy at most institutions. The diagnostic sensitivity of
molecular tests on swab samplesmay result inmisclassification error in
terms of criterion standard; however, the 30-day follow-up data should
help to clarify which patients suffered significant morbidity or mortal-
ity and help to mitigate this issue. The electronic surveillance method-
ology may miss important outcomes of patients who were discharged
from the index visit (eg, death at home or presentation to another
hospital out of state). Another limitation is the lack of consecutive
enrollment and the assumption that data not charted were negative.
Although registries can show associations, they have limited ability to
establish causal inference.19
4 DISCUSSION
The RECOVER registry will provide data describing the presenting
clinical characteristics and 30-day outcomes of over 30,000 US ED
patients tested for SARS-CoV-2. This database will serve as a resource
to create probabilistic tools for diagnosis and prognosis and to gener-
ate hypotheses about diverse aspects of theCOVID-19 pandemic.19 To
our knowledge, this will be the largest andmost geographically diverse
registry of patients with suspected COVID-19 in emergency care. The
Steering Committee and the site investigators debated, discussed, and
pilot-tested each question to ensure its scientific importance, clarity,
or adequate explanation by “field notes,” so that persons with mod-
est research experience could complete them with minimal training.
This was essential, given the need for remote training and data entry.
The fact that over 30,000 records from 45 sites have been uploaded
into REDCap between April and September 2020 suggests function-
ality of this data collection form. Each question was designed to be
scientifically important. In addition to producing the proposed CORC
rule and prognostic criteria, the RECOVER registry will allow risk ratio
calculations for patient demographics, COVID-19 exposure patterns,
social behaviors, medications, and medical conditions with respect to
the outcomes of infection and severe illness over the subsequent 30
days. Moreover, the RECOVER registry will provide a resource to test
the external validity of themany predictive and prognostic criteria that
have been published for COVID-19.20,21
Although many prognostic criteria have been proposed, a recent
systematic review of literature yielded an urgent need for high-quality
diagnostic and prognostic data for COVID-19.22 The authors note that
“Of 541 papers that reported clinical characteristics, 295 were com-
mentaries/expert opinions and 36 were case reports. There were no
randomized clinical trials, 45 case series studies, 58 narrative reviews,
1 cohort study, and 5 systematic reviews.”22 The RECOVER registry
may be unique because it includes ED patients who are both SARS-
CoV-2 positive, as well as those who had suspected COVID-19, but
who have negative diagnostic testing for SARS-CoV-2. This method-
ology specifically addresses the current critical need for a data set to
derive and test–pretest probability and exclusionary rules for COVID-
19, as has been done with many other diseases, notably pulmonary
embolism.23 The proposed CORC rule can be used to guide the deci-
sion whether to test or not, and assuming that accurate likelihood
ratios canbeproduced for diagnostic tests for SARS-CoV-2, the pretest
probability criteria derived from this work will allow an estimate of
post-test probability.6,24 With upcoming influenza, respiratory syncy-
tial, and other viral challenges approaching, the need for clinical crite-
ria to exclude or estimate the probability of COVID-19 may increase.
Therefore, evidence-based pretest probability criteria, an exclusionary
rule, and criteria to predict mild versus severe disease course, will be
important to facilitate prudent decisions about the optimal and safe
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location of post EDcare, timing of follow-up, or need for inpatientmon-
itoring for clinical deterioration.
Finally, in terms of ancillary (hypothesis-generating) work, the
RECOVER registry is a unique cooperative effort intended to be a pub-
lic resource to address many other questions. As one example, the
observation of increased risk of venous thromboembolism in critically
ill patients with COVID-19 patients has particular concern in emer-
gency care, becauseearly anticoagulationmay improveoutcomes.25–27
Opinions conflict about the use of empiric full-dose anticoagulation
for patients with known or suspected COVID-19.28–30 This debate is
at least partly fueled by the lack of data to estimate the risk ratio for
the short-term incidence of venous thromboembolism diagnosis after
a positive SARS-CoV-2 test, compared with symptomatic patients who
test negative for SARS-CoV-2 in the emergency care setting.31,32 The
RECOVER registry will directly address that knowledge gap. For ancil-
lary proposals, contributing sites in Figure 1 have first rights to sub-
mit for approval by the Steering Committee. After publication of the
initial set of manuscripts, in approximately June, 2021, we will open
theRECOVER registry to proposals from the general scientific commu-
nity. Data access will be free of monetary charge, but will be subject to
approval by the Steering Committee.
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